For Research Use Only. Not for human consumption.
You ran a cAMP assay, exported a clean file, typed an EC50 into a slide, and moved on. That is most runs.
This page explains what GLP-1R, GIPR, and GCGR assays are actually measuring — and why semaglutide, tirzepatide, and retatrutide do not tell one story just because every compound raises cAMP. Same family of receptors. Different experiments. We keep it practical, not a textbook chapter.
Start with the cells, not the compound
Before you compare semaglutide to tirzepatide on a graph, ask whose cells were in the well.
One receptor transfected. HEK293 or CHO cells expressing GLP-1R alone — clean, simple, where most published semaglutide EC50 numbers come from.
Two or three receptors transfected. Needed when your question is overlap. You cannot read tirzepatide data from this layout like it was a GLP-1-only plate.
Primary or native tissue. You get the whole neighborhood — often multiple incretin receptors at once. Fine for real biology. Rough for claiming one clean EC50.
No passage number from the week of the run? Treat the EC50 as a snapshot, not a law of nature.
How these peptides actually bind
GLP-1R, GIPR, and GCGR are Class B GPCRs. Big picture: the peptide binds in two steps.
Address. The C-terminal end docks on the outside of the receptor and lines the peptide up. Soft binding. Orientation, not activation.
Message. The N-terminal end reaches into the receptor core and turns signaling on. Clip the wrong end and you can see binding without cAMP moving — the peptide showed up and did not sign in.
That is why sequence edits matter on research analogs, whether the backbone is GLP-1 like semaglutide, GIP like tirzepatide, or glucagon like retatrutide.
GLP-1R and semaglutide
Most cAMP kits on GLP-1R transfectants measure one thing: Gs activation and the cAMP pile-up that follows. Native GLP-1(7-36) amide is potent here — picomolar EC50 in published HEK293 work.
The kit does not print the rest of the story on the export file. Receptors also desensitize — beta-arrestin recruitment shuts the signal down over time. Read the plate once at thirty minutes and two compounds can look identical. Read across time and they split.
Semaglutide is the GLP-1R reference tool everyone cites in methods sections: full agonism, picomolar EC50 in cAMP work, fatty-acid lipidation for albumin binding in solution. When you need one receptor and one clean comparison, this is the name on the shelf.
GIPR and tirzepatide
GIPR looks like GLP-1R on a slide — same receptor class, same cAMP pathway. Textbooks stop at the pancreas. Adipose and brain tissue tell a different story, which is partly why dual-agonist tools exist.
Tirzepatide is built on a GIP scaffold, not GLP-1. In published HEK293 work it is a strong GIPR agonist and a partial GLP-1R agonist — submaximal cAMP at GLP-1R even when the well looks saturated. Useful when you want GIPR fully on and GLP-1R only partly on in the same cells. Semaglutide cannot do that in one plate.
GCGR and retatrutide
GLP-1 rises after you eat. Glucagon rises when you have not. Both raise cAMP. The cell context still reads differently — fed versus fasted biochemistry is not the same homework assignment.
GCGR is big in liver; glucagon signaling there is the classic teaching example. Retatrutide is the triple-agonist name with the most in vitro papers: hits GLP-1R, GIPR, and GCGR, with GIPR strongest and GCGR needing higher concentration to fully engage. One vial, one dilution series, three levels of receptor occupancy — if your cells actually express all three.
Walk the plate before you trust the EC50
Same discipline as reading a COA. Top to bottom.
Passage number and thaw date — cells drift, peptides do not.
Clock time — cAMP peaks and falls; one read is a still frame from a movie you never shot.
PDE inhibitor in the buffer — boosts signal, also keeps it alive past natural shutoff. Know which question you are asking.
Endotoxin — dirty vials can make cells inflammatory before your compound does anything. A pretty curve on angry cells is still the wrong curve.
One open item means an open question. Answer it before the next order — not after the committee meeting.